Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
ArGEN-X
ArGEN-X
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
arGEN-X and LEO Pharma sign deal to develop antibody-based treatments for skin conditions
Dutch biotechnology company could potentially receive nearly €105m in payments
Research & Development
arGEN-X awarded €1.5m grant from IWT in Flanders
To advance the application of NHance Fc modifications in therapeutic antibodies
Manufacturing
Lonza signs multi-product agreement with arGEN-X for therapeutic antibodies
Building on a four-year relationship between the two companies
Research & Development
Shire signs monoclonal antibody agreement with arGEN-X
Will make an upfront payment to arGEN-X of €15m
Research & Development
arGEN-X to collaborate with Bayer
To discover and develop therapeutic antibody candidates
Research & Development
ArGEN-X appoints Werner Lanthaler to its Supervisory Board
He has been Chief Executive of Evotec for the past five years
Research & Development
ArGEN-X appoints David Lacey to supervisory board
Former head of discovery research at Amgen joins the Dutch firm
Subscribe now